A Randomized, Double-Blind, Parallel Group Study to Assess the Efficacy and Safety of Once Weekly Subcutaneous Injections of Pemziviptadil (PB1046), a Sustained-Release VIP (Vasoactive Intestinal Peptide) ANalogue, in Hospitalized COVID-19 Patients at HiGh Risk for Rapid Clinical Deterioration and ARDS (PB1046 VANGARD Study)

This is a multicenter, randomized, double-blind, parallel group study to investigate the efficacy of pemziviptadil (PB1046) by improving the clinical outcomes in hospitalized COVID-19 patients at high risk for rapid clinical deterioration, acute respiratory distress syndrome (ARDS) and death.
The study will enroll approximately 210 hospitalized COVID-19 patients who require urgent decision-making and treatment at approximately 20 centers in the United States.

开始日期2020-07-15

申办/合作机构

PhaseBio Pharmaceuticals, Inc.

NCT03795428

/ Terminated临床2期

A Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study PB1046-PT-CL-0004

This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose. This is a Long-Term, Open label Extension (OLE) Study for subjects with (PAH), having participated in double-blind Study PB1046-PT-CL-0004. The study will include adult subjects previously diagnosed with symptomatic PAH, who are receiving background clinician-directed therapy for PAH.
During this period, subjects will continue to be followed for safety and tolerability, as well as for periodic efficacy, quality of life data and immunogenicity. The study will continue per the schedule of events until such time when pemziviptadil (PB1046) is able to be self-administered, becomes commercially available to the subjects in a particular country or region, or the sponsor terminates the study due to lack of efficacy, safety or other reasons.

开始日期2019-04-10

申办/合作机构

PhaseBio Pharmaceuticals, Inc.

NCT03556020

/ Terminated临床2期

A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous (SC) Injections of a Sustained-Release Vasoactive Intestinal Peptide (VIP) Analogue, Pemziviptadil (PB1046), in Adult Subjects With Symptomatic Pulmonary Arterial Hypertension (PAH)

This is a multi-center, randomized, double-blind, controlled, Phase 2 study to assess the safety, tolerability, and efficacy of pemziviptadil (PB1046) at the optimally titrated dose after 16 weeks of treatment. Subjects will be randomized in a 2:1 ratio to one of two parallel dose groups: a) high-dose group where PB1046 will be up-titrated from a 0.2 mg/kg minimally effective starting dose to a target high dose level of at least 1.2 mg/kg or higher to a maximally tolerated dose (MTD), or b) a low-dose group that will start at 0.2 mg/kg and remain at this minimally effective dose (MED) level with sham up-titration. The total treatment period will be comprised of 2 phases: 1) an initial 10 week dose titration phase in which weekly doses of PB1046 will be titrated (or sham titrated) up to a target dose level of at least 1.2 mg/kg or higher to the MTD, and 2) a maintenance of treatment phase that begins when subjects reach week 11 and continues for 6 weeks during which no further up-titration should occur.

开始日期2018-07-15

申办/合作机构

PhaseBio Pharmaceuticals, Inc.

100 项与 PhaseBio Pharmaceuticals, Inc. 相关的临床结果

登录后查看更多信息

0 项与 PhaseBio Pharmaceuticals, Inc. 相关的专利（医药）

登录后查看更多信息

项与 PhaseBio Pharmaceuticals, Inc. 相关的文献（医药）

2022-10-03·European Heart Journal

A safety and pharmacodynamic study of the highly selective aldosterone synthase inhibitor PB6440 in the cynomolgus monkey

作者: Lee, J S ; Pacyniak, E ; Pitt, B ; Schotzinger, R J ; Bhatt, D L ; Jowett, J

AbstractBackgroundAldosterone is an important mediator of hypertension, particularly resistant hypertension, heart failure, and chronic kidney disease. PB6440 is a potent inhibitor of aldosterone synthase (CYP11B2) with high selectivity over the closely related enzyme CYP11B1. In previous studies in cynomolgus monkeys, PB6440 exhibited excellent oral bioavailability and a marked suppression of aldosterone synthesis at doses as low as 1 mg/kg/day. Importantly, no effect was observed on cortisol production nor significant changes noted in plasma concentrations of the steroid precursors 11-deoxycortisol or deoxycorticosterone (DOC), which are dependent on CYP11B1 activity. The purpose of the current study was to assess the safety and pharmacodynamics of higher doses of PB6440 in the cynomolgus monkey in order to determine a therapeutic index prior to initiation of studies in humans.MethodsMale and female cynomolgus monkeys (2/sex/dose group) were administered 0, 10, 30 or 100 mg/kg PB6440 once-daily for 14 days by oral gavage. Assessment of safety was based on mortality, clinical observations, body weights, and clinical and anatomic pathology. Blood samples were also collected for pharmacodynamic analysis, including aldosterone, cortisol, 11-deoxycortisol, DOC, and ACTH.ResultsPB6440 was well tolerated at all doses. There were no deaths and no reports of clinical observations at any dose level. Mild decreases in body weight were observed in PB6440-treated animals, which were likely due to the diuretic effects of the compound. PB6440 caused an increase in adrenal weights which was associated with hypertrophy of the adrenal zona fasciculata, a finding which has previously been observed with other aldosterone synthase inhibitors. PB6440 led to marked declines in basal aldosterone levels of −97%, −97% and −98% from baseline at 10, 30 and 100 mg/kg/day, respectively, at 24-hours following the final dose. Despite these clear declines in circulating aldosterone levels, no meaningful changes in cortisol, 11-deoxycortisol, DOC, or ACTH levels were observed, supporting lack of CYP11B1 inhibition. PB6440 led to expected decreases in plasma sodium (up to 7 nmol/L at the high dose). No effect on plasma potassium levels were observed at any dose level.ConclusionsPB6440 was well tolerated in the cynomolgus monkey at doses that are much higher than needed for potent aldosterone suppression based on previous studies. At the highest dose level tested (100 mg/kg), which led to a 98% reduction in basal aldosterone levels, no evidence of significant CYP11B1 inhibition was observed. The absence of an increase in plasma potassium in the presence of a plasma sodium decline merits further study. Thus, PB6440 is a highly selective novel aldosterone synthase inhibitor for the potential treatment of hypertension, heart failure, and chronic kidney disease in humans.Funding AcknowledgementType of funding sources: Public Institution(s). Main funding source(s): PhaseBio Pharmaceuticals Inc.

2022-10-03·European Heart Journal

Bentracimab demonstrates reversal of antiplatelet effects of ticagrelor: impact of hematocrit and generic versions of ticagrelor in vitro

作者: Lee, J ; Brown, R ; Bhatt, D ; Curry, B ; Jennings, L ; Arnold, S

Abstract Recent clinical studies demonstrated bentracimab provides immediate and sustained reversal of ticagrelor's antiplatelet effects in patients undergoing surgical procedures or with bleeding. Ticagrelor reversal was assessed by VerifyNow PRUTest (VN) and other platelet function testing assays in Phase I-III studies. As decreases in hematocrit (hct) may impact the VN result, it remains to be demonstrated whether this assay can detect platelet function restoration by bentracimab in bleeding patients with low hct. Additionally, bentracimab utility against generic ticagrelors is unknown. The purpose of this study was to determine the impact of decreased hct and generic forms of ticagrelor on platelet function and subsequent reversal by bentracimab, as measured by light transmission aggregometry (LTA) and VN. The hct level in blood samples collected from healthy volunteers (n=10) was sequentially lowered to 32, 30, 25, 22.5, 20 or 15% by addition of autologous platelet-rich plasma to whole blood with matching platelet counts. Prepared samples were treated with nothing, vehicle, or ticagrelor (3.0 μg/mL) followed by treatment with bentracimab (1.2 mg/mL). In a separate study, blood collected from healthy volunteers (n=10) was treated with nothing, vehicle, ticagrelor or generic ticagrelors (3.0 and 5.6 μg/mL; mean and peak plasma levels in the Phase 1 trial) prior to addition of bentracimab (0, 0.6, 1.2, 1.8 and 2.4 mg/mL; below the reported minimum to peak plasma level) to demonstrate a dose response. Reversal was assessed by either ADP-mediated LTA or VN or both assays. Results show a decrease in hct to <30% significantly increased the PRU in untreated samples (p<0.05). Ticagrelor treatment significantly decreased the PRU in all hct groups (p<0.0001). When normalized to each donor's baseline PRU values, bentracimab reversed the ticagrelor effects within 10-min, restoring the PRU value to 54–73% for all hct groups. PRU values were further restored to 85–93% of baseline PRU after 1-hr treatment. The PRU inhibition for both 10-min and 1-hr treatments were not significantly different across the hct groups, except for the 10-min treatment in the 15% hct group vs. unadjusted hct group (p<0.05), suggesting equivalent reversal by bentracimab across the hct range. In the second study, treatment with generic ticagrelor demonstrated significant platelet inhibition and was comparable to standard ticagrelor. Bentracimab (>0.6 mg/mL) immediately restored platelet function after ticagrelor treatment to 80–100% of baseline using the VN test. LTA data demonstrated similar results to VN, but as expected, reversal was less robust with 5.6 μg/mL ticagrelor + 0.6 mg/mL bentracimab combination (mean 55% of baseline values). Collectively, these data suggest the VN test can effectively measure the antiplatelet effects of ticagrelor and subsequent reversal, even at low hct, and bentracimab is also capable of reversing the antiplatelet effects of generic forms of ticagrelor.Funding AcknowledgementType of funding sources: Private company. Main funding source(s): PhaseBio Pharmaceuticals, Inc

2022-09-01·Hypertension

Abstract 121: The Selective Aldosterone Synthase Inhibitor PB6440 Normalizes Blood Pressure In A Human Aldosterone Synthase-Transgenic Mouse Model Of Hypertension

作者: Sparks, Steven ; Lee, John ; Du, Yansheng ; Schotzinger, Robert ; Gu, Huiying ; Yu, Yongqi ; Becherer, David

Introduction: Aldosterone synthase inhibitors are emerging as important future treatment options for diseases associated with aldosterone signaling, such as resistant hypertension and chronic renal disease. PB6440 is a potent inhibitor of aldosterone synthase (CYP11B2) with high selectivity over the closely related enzyme CYP11B1. The goal of the current study was to determine whether PB6440 was capable of reducing aldosterone production and blood pressure in an established human aldosterone synthase-transgenic mouse strain (hAS +/- ) that is associated with aldosterone excess and the development of hypertension under a 4% salt diet. Methods: hAS +/- mice were administered PB6440, positive controls and vehicle by oral gavage. In a single-dose study, plasma aldosterone levels were assessed 8 hours after the administration of PB6440 at 2, 10 and 30 mg/kg as well as the positive control fadrozole at 5 mg/kg. In a pilot study, blood pressure was assessed following 10 days of PB6440 once daily at 10 mg/kg as well as the positive control spironolactone at 50 mg/kg. In a definitive study, blood pressure was assessed following 8 weeks of PB6440 once daily at 30 mg/kg as well as spironolactone at 50 mg/kg. Blood pressure was assessed 4-6 hours after drug dosing using a tail-cuff system. Results: In the single-dose study, PB6440 markedly reduced plasma aldosterone with a similar potency to fadrozole (e.g., PB6440 10 mg/kg -96% compared to vehicle; fadrozole 5 mg/kg -96%). In the pilot study, PB6440 normalized both systolic and diastolic blood pressures to that of wild-type mice, with a somewhat greater effect on both parameters than spironolactone at day 10. In the definitive study, PB6440 normalized both systolic and diastolic blood pressures to that of wild-type mice through 8 weeks with an efficacy similar to spironolactone. The decreases in SBP were approximately 30 mm Hg and DBP approximately 20 mm Hg in both drug groups compared to vehicle-treated hAS +/- mice. Conclusions: PB6440 was shown to lower aldosterone levels and normalize blood pressure through 8 weeks in an established mouse model of aldosterone excess and hypertension. PB6440 is a promising potential therapy for the treatment of conditions associated with aldosterone signaling in humans.

项与 PhaseBio Pharmaceuticals, Inc. 相关的新闻（医药）

2024-06-11

·CPHI制药在线

醛固酮合成酶抑制剂进展浅谈，或为难治性高血压、CKD新选择

关注并星标CPHI制药在线醛固酮是人类肾上腺皮质球状带区域分泌的一种盐皮质激素，通过调节肾脏对钠离子的重吸收，维持水盐平衡。过量的醛固酮不适当地激活盐皮质激素受体，会增加血浆体积，导致血压升高。此外，醛固酮水平过高会造成心肌及血管间质纤维化，导致心室和血管重构，诱发白细胞浸润造成及冠脉和心肌损伤、心律失常。醛固酮合成酶（AS，由CYP11B2基因编码) 控制醛固酮的合成，几十年来一直是治疗高血压的药理学靶点。但由于产生醛固酮的酶和产生皮质醇的酶有93%是相同的，高选择性醛固酮合成酶的研发一直没有突破性进展。据不完全统计，目前全球药企已研发出几款醛固酮合成酶抑制剂（详见下表），这几款药物主要被开发用于治疗难治性高血压以及慢性肾脏病，其中三款已进入3期临床。具体品种上，BI 690517是一种新型强效的醛固酮合成酶抑制剂，其设计具有高选择性，可潜在减缓慢性肾病（CKD）患者的肾损害进展并减少心血管事件。已公布的BI 690517治疗CKD的2期临床试验结果显示：无论是否联合SGLT2抑制剂，BI 690517均可降低蛋白尿，且安全性良好。此外，无论是否联合恩格列净治疗，BI 690517均可显著降低血浆醛固酮水平。具体数据为：14周时，在恩格列净为背景治疗基础上，10 mg BI 690517治疗组经安慰剂校正后首次晨尿的尿白蛋白/肌酐比值（UACRFMV）中位值降幅度高达 -39.5%，其中高达70%患者实现UACRFMV降幅≥30%；而在未联合恩格列净治疗组中，BI 690517最高可使51%患者实现UACRFMV降幅≥30%。 Baxdrostat是一种小分子高选择性醛固酮合酶抑制剂，能够高选择性抑制醛固酮合成酶，而不会阻断盐皮质激素受体，被开发用于治疗难治性高血压、原发性醛固酮增多症（Spark-PA）以及慢性肾病（CKD）合并高血压。临床前和1期研究表明，与皮质醇合成酶相比，Baxdrostat对醛固酮合成酶具有非常高的选择性（100:1），多个剂量水平的baxdrostat可降低血浆醛固酮水平，但不降低皮质醇水平。而且，Baxdrostat安全性、耐受性良好，半衰期支持每日一次给药。已公布的Baxdrostat治疗难治性高血压的2期临床研究BrigHTN结果显示：Baxdrostat可剂量依赖性的降低难治性高血压患者的血压和血醛固酮水平。值得一提的是，Baxdrostat由CinCor Pharma开发，2023年1月阿斯利康斥资18亿美元收购CinCor Pharma将Baxdrostat纳入囊中。阿斯利康积极探索Baxdrostat联合SGLT2抑制剂达格列净（dapagliflozin）的治疗潜力，目前该组合疗法用于延缓CKD合并高血压成人患者肾功能下降的3期临床试验已经启动。 Lorundrostat（MLS-101）一种高选择性、强效醛固酮合酶抑制剂，2020年Mineralys Therapeutics从Mitsubishi Tanabe获得该药的授权。已公布的Lorundrostat治疗难治性高血压的2期临床研究Target-HTN结果显示：每天口服一次loundrostat可使难治性高血压患者的血压显著降低。具体数据为：在意向性治疗群体中，12.5 mg、50 mg和100mg治疗组患者经安慰剂调整的收缩压下降水平分别为1.4 mmHg（未达统计显著水平）、9.7 mmHg（p=0.010）和7.9 mmHg（p=0.037）。而且，肥胖患者服用lorundrostat后血压下降幅度更大：对于BMI≥30 kg/m2的高血压患者，与安慰剂相比，50 mg和100mg lorundrostat治疗组患者的收缩压分别降低16.7 mmHg (p=0.002)和12.3 mmHg (p=0.030)。在亚群分析中，当患者同时使用噻嗪类利尿剂作为背景治疗时，loundrostat疗效更为显著，12.5 mg、50 mg和100mg治疗组经安慰剂调整的收缩压下降水平分别为5.3 mmHg（未达统计显著水平）、13.2 mmHg（p=0.010）和11.4 mmHg（p=0.028）。此外，loundrostat也可降低患者的舒张压、24小时动态血压、夜间收缩压等。 JX09是新一代高选择性醛固酮合成酶抑制剂，临床前研究结果显示其能高效抑制醛固酮合成酶，并极少与机体内的同源酶发生作用，降低该抑制剂对皮质醇路径的影响。 2023年2月，箕星药业通过收购PhaseBio获得PB6440的全球权益。2024年2月，该药在澳大利亚开展的1期临床试验首例受试者成功给药。总结整体来看，在研醛固酮合成酶抑制剂并不多，但同靶点间药物间竞争激烈，三款处于3期临床，目前无法预测谁将率先出线。此外，醛固酮合成酶抑制剂除被开发作为单药疗法，还有望联合SGLT2抑制剂、噻嗪类利尿剂等药物治疗慢性肾脏病、难治性高血压等。【企业推荐】【智药研习社直播预告】来源：CPHI制药在线声明：本文仅代表作者观点，并不代表制药在线立场。本网站内容仅出于传递更多信息之目的。如需转载，请务必注明文章来源和作者。投稿邮箱：Kelly.Xiao@imsinoexpo.com ▼更多制药资讯，请关注CPHI制药在线▼ 点击阅读原文，进入智药研习社~

临床2期临床1期临床终止临床结果临床3期

2024-04-11

·PRNewswire

Nuevocor Strengthens Leadership Team with Appointment of John Lee as Chief Medical Officer

SINGAPORE and PHILADELPHIA, April 9, 2024 /PRNewswire/ -- Nuevocor, a pre-clinical stage biotechnology company dedicated to developing novel medicines to treat cardiomyopathies with aberrant mechanobiology, today announces the appointment of Dr. John Lee, MD, PhD, as its Chief Medical Officer. Dr. Lee is a life science executive with experience spanning from early drug discovery to late-stage clinical development. Dr. John Lee is a board-certified cardiologist who brings over 15 years of clinical development and regulatory expertise to Nuevocor. Dr. Lee was most recently the Chief Medical Officer of PhaseBio Pharmaceuticals, a publicly listed biotech, where he led Phase I-III development of its clinical programs. Prior to PhaseBio, Dr. Lee was the Vice President, Global Head, Cardiovascular Center of Excellence at Quintiles, where he was responsible for developing and implementing the cardiovascular therapeutic area business growth strategy and also represented their cardiovascular therapeutic expertise across the broader enterprise and in the global marketplace. Dr. Lee also served as Executive Director, Discovery Medicine at Bristol-Myers Squibb ("BMS"), where he was responsible for leading the team that provided medical, clinical, scientific, regulatory and R&D advisory expertise in cardiovascular drug development across BMS. Having held key leadership roles in both biotech and pharmaceutical sectors, Dr. Lee is poised to spearhead Nuevocor's clinical development strategy and advance its innovative therapies for LMNA DCM through rigorous clinical development oversight and execution. "Dr. Lee's appointment marks a significant milestone for Nuevocor," said Dr. Yann Chong Tan, PhD, CEO and Co-Founder of Nuevocor. "His extensive experience and proven track record in clinical development make him the ideal candidate to lead our clinical development team. His leadership will be instrumental in furthering our commitment to advancing science and translating it into therapies that will make a real difference in patients' lives." "I am honored to join Nuevocor at this pivotal moment," said Dr. John Lee. "The opportunity to lead the clinical development efforts for the LMNA DCM program is incredibly motivating. I look forward to collaborating with the talented team at Nuevocor to bring potentially life-changing therapies to patients." About Nuevocor Nuevocor is a biotechnology company that is pioneering an innovative pathway-centric approach to developing genetic medicines for heart conditions known as cardiomyopathies. By harnessing our PrOSIA™ mechanobiology platform, Nuevocor designs genetic medicines to target the biomechanical root cause of these diseases. Nuevocor's approach surpasses the limitations of traditional gene therapy, which focuses on individual gene mutations, to treat defects within shared disease pathways across multiple genetic cardiomyopathies. This enables us to extend our impact to broader patient populations. SOURCE Nuevocor

高管变更

2024-03-02

·PRNewswire

Global Acute Heart Failure (AHF) Therapeutics Research Report 2022-2024 and 2030: Conventional Therapies Leave Considerable Unmet Needs, Novel Treatments Offer a Ray of Hope

DUBLIN, March 1, 2024 /PRNewswire/ -- The "Acute Heart Failure (AHF) Therapeutics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Acute Heart Failure (AHF) Therapeutics Market to Reach $2.9 Billion by 2030 The global market for Acute Heart Failure (AHF) Therapeutics estimated at US$599.7 Million in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 21.7% over the analysis period 2022-2030. Cardiac Glycosides, one of the segments analyzed in the report, is projected to record a 22.3% CAGR and reach US$762.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the B-Blockers segment is readjusted to a revised 25.1% CAGR for the next 8-year period. The acute heart failure (AHF) market has been significantly impacted by the COVID-19 pandemic and the looming global recession. Despite the challenges, diuretics and vasodilators remain the first-line therapy for AHF, although the efficacy of other known drugs for AHF is limited, hindering their widespread use. Market insights and trajectories indicate a complex landscape influenced by these factors, with varying degrees of competitive market presence among players worldwide in 2022. Recent market activity reflects ongoing efforts to size the AHF market and adapt to the evolving healthcare landscape. Looking ahead, the market outlook suggests continued focus on addressing the challenges posed by COVID-19 and economic uncertainties while exploring opportunities for innovation and growth in AHF therapeutics. The U.S. Market is Estimated at $163.4 Million, While China is Forecast to Grow at 30.4% CAGR The Acute Heart Failure (AHF) Therapeutics market in the U.S. is estimated at US$163.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$841.2 Million by the year 2030 trailing a CAGR of 30.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 16.3% and 18.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 17.1% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433.4 Million by the year 2030. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Market Outlook Recent Market Activity Sizing the AHF Market Acute Heart Failure - An Overview of the Disease and Available Therapeutics Diuretics and Vasodilators - The First Line Therapy for AHF Other Known Drugs for AHF - Lower Efficacy Thwarts Use Acute Heart Failure (AHF) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession MARKET TRENDS & DRIVERS Conventional Therapies Leave Considerable Unmet Needs Novel Treatments Offer a Ray of Hope Key AHF Therapeutics in the Pipeline Serelaxin Nears Trial Readout form RELAX-AHF-2 Ularitide - A Novel Drug in Development for AHF The Litany of Drug Failures Expands, Emphasis on Prevention Grows Other Promising Drugs under Development Research Findings Kidney Dysfunction - Predictor of Acute Heart failure Genetic Influence on Heart Disease among African Americans Higher Body Mass Index - A Key Risk Factor for AHF Supplemental Oxygen Therapy May not be for All Cases of AHF Macro Growth Drivers Alarming Levels of Cardiovascular Disease (CVD) Prevalence: Key Growth Driver for AHF Therapeutics Ballooning Elderly Population: The Vital Growth Driver for AHF Therapeutics FOCUS ON SELECT PLAYERS (Total 93 Featured) Bayer AG (Germany) Bristol-Myers Squibb Company (USA) Cardiorentis AG (Switzerland) CVie Therapeutics Limited (Taiwan) Cytokinetics, Inc. (USA) Merck & Co. (USA) Novartis AG (Switzerland) Orion Corporation (Finland) PhaseBio Pharmaceuticals, Inc. (USA) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

AHA会议

100 项与 PhaseBio Pharmaceuticals, Inc. 相关的药物交易

登录后查看更多信息

100 项与 PhaseBio Pharmaceuticals, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年01月26日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

临床1期

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

CNP-ELP ( NPRA )	软骨发育不全更多	临床1期
PE-0503 ( GLP-2R )	克罗恩病更多	临床前
PB-6440 ( ALDOS )	高血压更多	临床前
Vasomera ( VIPR2 )	肺水肿更多	终止
PE-0139 ( INSR )	2型糖尿病更多	无进展